Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus ...

Detailed price information for Cogent Biosciences Inc (COGT-Q) from The Globe and Mail including charting and trades.

About The Study: The findings of this study suggest a narrowing of racial and ethnic disparities in receipt of ERBB2 (formerly HER2 or HER2/neu)-targeted therapies over time among older Medicare ...

Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer ...

Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer ...

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC Ingelheim, Germany / Ridgefield, Conn., U ...

Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer ...

TOPLINE: Higher tumor-infiltrating lymphocyte (TIL) levels were independently associated with improved overall survival in patients with early-stage ERBB2-positive breast cancer.

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...

One reason that patients with ERBB2-amplified metastatic colorectal cancer (mCRC) do not respond to HER2-targeted therapies is the presence of pathological ERBB2 variants that render the ...